Do opioids activate latent HIV-1 by down-regulating anti-HIV microRNAs?

Area of Science:

• Virology
• Immunology
• Molecular Biology

Background:

• HIV-1 primarily infects monocytes, macrophages, and CD4+ T cells.
• Specific microRNAs (miRNAs) are present in these cells and influence HIV-1 infectivity and latency.
• These anti-HIV miRNAs show differential expression in resting versus active immune cells and in monocytes versus macrophages.

Purpose of the Study:

• To investigate the role of anti-HIV miRNAs in regulating HIV-1 infectivity and latency.
• To examine the effect of morphine on the expression of anti-HIV miRNAs.
• To explore the potential implications of morphine's effect on latent HIV-1 reactivation.

Main Methods:

• Analysis of anti-HIV miRNA levels in monocytes, macrophages, and CD4+ T cells.
• Assessment of HIV-1 infectivity in relation to miRNA expression.
• Investigation of morphine's effect on miRNA expression in cultured human monocytes via mu opioid receptors (MOR).
• Comparison of miRNA levels in peripheral blood mononuclear cells (PBMCs) from heroin-dependent subjects and controls.

Main Results:

• Anti-HIV miRNAs (miR-28, miR-125b, miR-150, miR-223, miR-382) are present in HIV-1 target cells and modulate infectivity and latency.
• miRNA levels are inversely correlated with HIV-1 infectivity in CD4+ T cells and monocytes/macrophages.
• Morphine down-regulates anti-HIV miRNA expression through MOR activation.
• Lower anti-HIV miRNA levels were observed in heroin-dependent individuals.

Conclusions:

• Anti-HIV miRNAs play a critical role in controlling HIV-1 replication and latency.
• Morphine's ability to down-regulate these miRNAs raises concerns about potential reactivation of latent HIV-1.
• Further research is needed to determine if morphine can activate latent HIV-1 in patients on HAART.